- Home
- PRPH vs CHRO Comparison
PRPH vs CHRO Comparison
Compare PRPH & CHRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRPH
- CHRO
- Stock Information
- Founded
- PRPH 1989
- CHRO 2002
- Country
- PRPH United States
- CHRO United States
- Employees
- PRPH N/A
- CHRO N/A
- Industry
- PRPH Biotechnology: Pharmaceutical Preparations
- CHRO
- Sector
- PRPH Health Care
- CHRO
- Exchange
- PRPH Nasdaq
- CHRO Nasdaq
- Market Cap
- PRPH 10.7M
- CHRO 10.7M
- IPO Year
- PRPH 1997
- CHRO 2024
- Fundamental
- Price
- PRPH $0.43
- CHRO $1.71
- Analyst Decision
- PRPH
- CHRO Strong Buy
- Analyst Count
- PRPH 0
- CHRO 1
- Target Price
- PRPH N/A
- CHRO N/A
- AVG Volume (30 Days)
- PRPH 27.1M
- CHRO 29.0K
- Earning Date
- PRPH 03-18-2025
- CHRO 03-18-2025
- Dividend Yield
- PRPH N/A
- CHRO N/A
- EPS Growth
- PRPH N/A
- CHRO N/A
- EPS
- PRPH N/A
- CHRO N/A
- Revenue
- PRPH $12,753,000.00
- CHRO N/A
- Revenue This Year
- PRPH $36.93
- CHRO N/A
- Revenue Next Year
- PRPH $132.05
- CHRO N/A
- P/E Ratio
- PRPH N/A
- CHRO N/A
- Revenue Growth
- PRPH N/A
- CHRO N/A
- 52 Week Low
- PRPH $0.22
- CHRO $0.45
- 52 Week High
- PRPH $7.48
- CHRO $3.80
- Technical
- Relative Strength Index (RSI)
- PRPH 48.83
- CHRO 45.55
- Support Level
- PRPH $0.31
- CHRO $1.59
- Resistance Level
- PRPH $0.46
- CHRO $2.36
- Average True Range (ATR)
- PRPH 0.07
- CHRO 0.24
- MACD
- PRPH 0.00
- CHRO -0.06
- Stochastic Oscillator
- PRPH 46.28
- CHRO 13.91
About PRPH ProPhase Labs Inc. (DE)
ProPhase Labs Inc is a diversified company that offers a range of services including diagnostic testing, genomics testing and contract manufacturing. Its operating segments include Diagnostic services and Consumer products. The Diagnostic segment provides COVID-19 diagnostic information services to a broad range of customers in the United States, including health plans, third-party payers and government organizations. The Consumer products segment is engaged in the research, development, manufacture, distribution, marketing and sale of OTC consumer healthcare products and dietary supplements in the United States and also provide personal genomics products and services.
About CHRO Chromocell Therapeutics Corporation
Channel Therapeutics Corp is a clinical-stage biotechnology company developing and commercializing novel, non-opioid, non-addictive therapeutics to alleviate pain. The initial clinical focus is to selectively target the sodium ion channel known as NaV1.7 for the treatment of various types of chronic pain, acute and chronic eye pain, and post-surgical nerve blocks. Its pipeline includes CC8464 for ISFN and EM and CT2000 for Acute and CHronic Eye Pain-Dry Eye Disease.